Clinical trial · Interventional
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic tumor vaccine and patients who continue to receive FOLFIRINOX. Funding Source - FDA Office of Orphan Product Development (OOPD)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FOLFIRINOX | Drug | — | UNRESOLVED |
| Ipilimumab | Drug | Ipilimumab | ALIAS |
| Vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Ipilimumab + Vaccine (Arm A)
- description
- Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
- interventionNames
- Drug: Ipilimumab
- Biological: Vaccine
- type
- EXPERIMENTAL
- label
- FOLFIRINOX (Arm B)
- description
- Administered every 14 days (one cycle)
- interventionNames
- Drug: FOLFIRINOX
Primary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- 4 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria (abbreviated): 1. Documented adenocarcinoma of the pancreas 2. Stable metastatic pancreatic cancer after 8-12 doses of FOLFIRINOX 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4. Life expectancy greater than 3 months 5. Adequate organ and marrow function defined by study-specified laboratory tests. 6. Must use acceptable form of birth control while on study 7. Oxygen saturation on room air \>92% Exclusion Criteria (abbreviated): 1. Surgery within 4 weeks of dosing investigational agent (some exceptions for minor procedures) 2. Off FOLFIRINOX treatment for more than 70 days prior to treatment on study 3. Prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX or adjuvant therapy). 4. History of prior treatment with ipilimumab, anti-PD1 antibody, CD137 agonist, or anti-CD40 antibody 5. Received any non-oncology live vaccine therapy up to one month prior to or after any dose of ipilimumab/vaccine 6. Receiving any other investigational agents 7. Any of the following concomitant therapy: IL-2, interferon, immunosuppressive agents, or chronic use of systemic corticosteroids 8. History of symptomatic autoimmune disease or immune impairment. Thyroid disease is allowed. 9. Known brain metastasis 10. Radiographic ascites that is apparent on physical exam or requiring intervention in the 2 months prior to enrollment 11. Uncontrolled intercurrent illness 12. Known or suspected hypersensitivity to GM-CSF 13. Chronic HIV, Hepatitis B or Hepatitis C 14. Pregnant or breastfeeding women
References
Publications (0)
Data not yet available